Although the draft discussionquestionsfor the committee mostly focus on the safety issues, I suspect that the efficacy data will actually play a more important role in determining how the committee votes.
The issues surrounding Geithner will undoubtedly draw much congressional discussion and raise questions about Obama's vetting process for his Cabinet nominees.